Home LiteratureArticle Details
PMID: 22001110 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Functions and regulation of the APOBEC family of proteins.

Seminars in cell & developmental biology ·Vol. 23 ·No. 3 ·2012-05-00 ·Pages 258-68

Smith HC, Bennett RP, Kizilyer A, McDougall WM, Prohaska KM

Abstract

APOBEC1 is a cytidine deaminase that edits messenger RNAs and was the first enzyme in the APOBEC family to be functionally characterized. Under appropriate conditions APOBEC1 also deaminates deoxycytidine in single-stranded DNA (ssDNA). The other ten members of the APOBEC family have not been fully characterized however several have deoxycytidine deaminase activity on ssDNAs. Despite the nucleic acid substrate preferences of different APOBEC proteins, a common feature appears to be their intrinsic ability to bind to RNA as well as to ssDNA. RNA binding to APOBEC proteins together with protein-protein interactions, post-translation modifications and subcellular localization serve as biological modulators controlling the DNA mutagenic activity of these potentially genotoxic proteins.

MeSH Terms
Animals Cytidine Deaminase/chemistry,metabolism DNA, Single-Stranded/metabolism Humans RNA/metabolism RNA Editing
Chemicals
DNA, Single-Stranded RNA Cytidine Deaminase
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Smith Harold C
Department of Biochemistry and Biophysics, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA. harold.smith@rochester.edu
Bennett Ryan P
Kizilyer Ayse
McDougall William M
Prohaska Kimberly M
References (145)
145 references, click to expand
  1. Selective inhibition of Alu retrotransposition by APOBEC3G.
    Gene. 2007 Apr 1;390(1-2):199-205 PMID: 17079095
  2. Only cytidines 5' of the apolipoprotein B mRNA mooring sequence are edited.
    Biochim Biophys Acta. 1994 Sep 13;1219(1):1-14 PMID: 8086446
  3. Complementary function of the two catalytic domains of APOBEC3G.
    Virology. 2005 Mar 15;333(2):374-86 PMID: 15721369
  4. The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors.
    J Cell Sci. 2002 Mar 1;115(Pt 5):1027-39 PMID: 11870221
  5. Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members.
    J Biol Chem. 2007 Nov 16;282(46):33632-33640 PMID: 17848567
  6. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
    J Virol. 2007 Apr;81(8):3807-15 PMID: 17267497
  7. APOBEC3G: a double agent in defense.
    Trends Biochem Sci. 2011 May;36(5):239-44 PMID: 21239176
  8. The interaction between HIV-1 Gag and APOBEC3G.
    J Biol Chem. 2004 Aug 6;279(32):33177-84 PMID: 15159405
  9. Increasing the yield of soluble recombinant protein expressed in E. coli by induction during late log phase.
    Biotechniques. 2003 Mar;34(3):524-6, 528, 530 PMID: 12661158
  10. Molecular cloning of an apolipoprotein B messenger RNA editing protein.
    Science. 1993 Jun 18;260(5115):1816-9 PMID: 8511591
  11. APOBEC3 proteins inhibit human LINE-1 retrotransposition.
    J Biol Chem. 2006 Aug 4;281(31):22161-22172 PMID: 16735504
  12. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity.
    Cell. 2002 Apr;109 Suppl:S35-44 PMID: 11983151
  13. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  14. Adenosine-to-inosine RNA editing shapes transcriptome diversity in primates.
    Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12174-9 PMID: 20566853
  15. AID mutant analyses indicate requirement for class-switch-specific cofactors.
    Nat Immunol. 2003 Sep;4(9):843-8 PMID: 12910268
  16. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
    Hepatology. 2007 Dec;46(6):1810-20 PMID: 17847074
  17. The apolipoprotein B mRNA editing complex performs a multifunctional cycle and suppresses nonsense-mediated decay.
    EMBO J. 2003 Aug 1;22(15):3971-82 PMID: 12881431
  18. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1).
    J Biol Chem. 2003 May 30;278(22):19583-6 PMID: 12697753
  19. Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene.
    Genomics. 2000 Aug 15;68(1):85-8 PMID: 10950930
  20. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone.
    Blood. 2003 Nov 1;102(9):3333-9 PMID: 12855567
  21. CTNNBL1 is a novel nuclear localization sequence-binding protein that recognizes RNA-splicing factors CDC5L and Prp31.
    J Biol Chem. 2011 May 13;286(19):17091-102 PMID: 21385873
  22. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
    PLoS One. 2009;4(1):e4277 PMID: 19169351
  23. Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis.
    Int J Cancer. 2012 Mar 15;130(6):1294-301 PMID: 21469143
  24. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.
    J Virol. 2011 Feb;85(4):1765-76 PMID: 21123384
  25. Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity.
    J Biol Chem. 2001 Dec 7;276(49):46386-93 PMID: 11571303
  26. The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1.
    Proc Natl Acad Sci U S A. 2004 May 25;101(21):8114-9 PMID: 15148397
  27. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses.
    Nucleic Acids Res. 2006 Mar 14;34(5):1522-31 PMID: 16537839
  28. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol. 2004 Nov;78(21):11841-52 PMID: 15479826
  29. Measuring editing activity and identifying cytidine-to-uridine mRNA editing factors in cells and biochemical isolates.
    Methods Enzymol. 2007;424:389-416 PMID: 17662851
  30. Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1.
    J Biol Chem. 1996 Oct 18;271(42):25981-8 PMID: 8824235
  31. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    J Biol Chem. 2004 Aug 20;279(34):35822-8 PMID: 15210704
  32. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells.
    J Biol Chem. 1999 Jun 25;274(26):18470-6 PMID: 10373455
  33. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein.
    J Biol Chem. 1995 Jun 16;270(24):14762-7 PMID: 7782342
  34. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.
    Trends Genet. 2003 Apr;19(4):207-16 PMID: 12683974
  35. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
    J Biol Chem. 2006 Jun 23;281(25):16837-16841 PMID: 16648136
  36. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
    J Biol Chem. 2008 Mar 21;283(12):7320-7 PMID: 18165230
  37. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4102-7 PMID: 12651944
  38. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing.
    Nucleic Acids Res. 1996 Feb 1;24(3):478-85 PMID: 8602361
  39. Molecular diversity through RNA editing: a balancing act.
    Trends Genet. 2010 May;26(5):221-30 PMID: 20395010
  40. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.
    J Biol Chem. 2006 Dec 15;281(50):38122-6 PMID: 17079235
  41. Activation-induced cytidine deaminase splice variants are defective because of the lack of structural support for the catalytic site.
    J Immunol. 2010 Mar 1;184(5):2487-91 PMID: 20118283
  42. AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):7003-8 PMID: 12011459
  43. Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.
    J Virol. 2010 Dec;84(24):12903-13 PMID: 20926562
  44. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest.
    EMBO Rep. 2011 May;12(5):444-50 PMID: 21460793
  45. Targeting of somatic hypermutation.
    Nat Rev Immunol. 2006 Aug;6(8):573-83 PMID: 16868548
  46. Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation.
    J Biol Chem. 1991 Oct 25;266(30):20550-4 PMID: 1939106
  47. Insights into the B cell specific process of immunoglobulin class switch recombination.
    Immunol Lett. 2011 Aug 30;138(2):97-103 PMID: 21324342
  48. Role of AID in tumorigenesis.
    Adv Immunol. 2007;94:245-73 PMID: 17560277
  49. Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif.
    J Biol Chem. 1996 May 10;271(19):11506-10 PMID: 8626710
  50. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.
    Mol Cell. 2002 Nov;10(5):1247-53 PMID: 12453430
  51. Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion.
    Science. 2002 Feb 15;295(5558):1301-6 PMID: 11847344
  52. The APOBEC-2 crystal structure and functional implications for the deaminase AID.
    Nature. 2007 Jan 25;445(7126):447-51 PMID: 17187054
  53. Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation.
    Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12079-84 PMID: 19581596
  54. B-cell receptor activation inhibits AID expression through calmodulin inhibition of E-proteins.
    Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1267-72 PMID: 18203819
  55. C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.
    Am J Hum Genet. 2002 Jan;70(1):38-50 PMID: 11727199
  56. Apolipoprotein B RNA sequence 3' of the mooring sequence and cellular sources of auxiliary factors determine the location and extent of promiscuous editing.
    Nucleic Acids Res. 1998 Apr 1;26(7):1644-52 PMID: 9512534
  57. Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase.
    J Exp Med. 2004 May 3;199(9):1235-44 PMID: 15117971
  58. Activation-induced cytidine deaminase splicing patterns in chronic lymphocytic leukemia.
    Blood Cells Mol Dis. 2010 Apr 15;44(4):262-7 PMID: 20117026
  59. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  60. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme.
    Genes Dev. 1997 Feb 1;11(3):321-33 PMID: 9030685
  61. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.
    J Virol. 2006 Jun;80(12):5992-6002 PMID: 16731938
  62. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.
    FASEB J. 2009 Jan;23(1):279-87 PMID: 18827027
  63. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling.
    Oncogene. 2007 Aug 16;26(38):5587-95 PMID: 17404578
  64. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.
    PLoS Pathog. 2009 Mar;5(3):e1000330 PMID: 19266078
  65. Immunology. One AID to unite them all.
    Science. 2002 Feb 15;295(5558):1244-5 PMID: 11847327
  66. Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90.
    J Exp Med. 2010 Nov 22;207(12):2751-65 PMID: 21041454
  67. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging.
    J Mol Biol. 2008 Jan 25;375(4):1098-112 PMID: 18067920
  68. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
    J Virol. 2006 Nov;80(21):10522-33 PMID: 16920826
  69. Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing.
    J Biol Chem. 2002 Apr 12;277(15):12703-9 PMID: 11815617
  70. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.
    Cell. 2000 Sep 1;102(5):553-63 PMID: 11007474
  71. Identification of domains in apobec-1 complementation factor required for RNA binding and apolipoprotein-B mRNA editing.
    RNA. 2002 Jan;8(1):69-82 PMID: 11871661
  72. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis.
    Cell Cycle. 2005 Sep;4(9):1281-5 PMID: 16082223
  73. Intracellular trafficking determinants in APOBEC-1, the catalytic subunit for cytidine to uridine editing of apolipoprotein B mRNA.
    Exp Cell Res. 2001 Jul 15;267(2):153-64 PMID: 11426934
  74. Immunology. Antibody alterations.
    Nature. 2001 Aug 30;412(6850):870-1 PMID: 11528462
  75. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs.
    Nat Struct Mol Biol. 2011 Feb;18(2):230-6 PMID: 21258325
  76. Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1.
    Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1975-80 PMID: 14769937
  77. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.
    J Virol. 2006 Apr;80(8):3853-62 PMID: 16571802
  78. Genetic algorithm learning as a robust approach to RNA editing site prediction.
    BMC Bioinformatics. 2006 Mar 16;7:145 PMID: 16542417
  79. Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing.
    Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13075-80 PMID: 9371802
  80. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon.
    Science. 1987 Oct 16;238(4825):363-6 PMID: 3659919
  81. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.
    Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9854-9 PMID: 16000409
  82. Molecular mechanisms of antibody somatic hypermutation.
    Annu Rev Biochem. 2007;76:1-22 PMID: 17328676
  83. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
    Virology. 2008 Jul 20;377(1):71-9 PMID: 18495196
  84. An additional editing site is present in apolipoprotein B mRNA.
    Nucleic Acids Res. 1991 Apr 25;19(8):1741-4 PMID: 1851558
  85. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms.
    J Biol Chem. 2010 Sep 3;285(36):27753-66 PMID: 20615867
  86. A novel nuclear localization signal in the auxiliary domain of apobec-1 complementation factor regulates nucleocytoplasmic import and shuttling.
    J Biol Chem. 2003 Oct 17;278(42):41198-204 PMID: 12896982
  87. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
    J Biol Chem. 2004 Aug 13;279(33):34083-6 PMID: 15215254
  88. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.
    J Biol Chem. 2007 Feb 9;282(6):3539-46 PMID: 17110377
  89. APOBEC3 proteins: major players in intracellular defence against LINE-1-mediated retrotransposition.
    Biochem Soc Trans. 2007 Jun;35(Pt 3):637-42 PMID: 17511669
  90. Restriction of foamy viruses by APOBEC cytidine deaminases.
    J Virol. 2006 Jan;80(2):605-14 PMID: 16378963
  91. Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity.
    Biochem Biophys Res Commun. 2011 Sep 9;412(4):612-7 PMID: 21856286
  92. Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site.
    Cell. 1995 Apr 21;81(2):187-95 PMID: 7736571
  93. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Curr Biol. 2004 Aug 10;14(15):1385-91 PMID: 15296757
  94. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48.
    J Biol Chem. 1996 Apr 26;271(17):9887-90 PMID: 8626621
  95. Determinants involved in regulating the proportion of edited apolipoprotein B RNAs.
    RNA. 1996 Mar;2(3):274-88 PMID: 8608451
  96. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
    J Biol Chem. 2006 Sep 29;281(39):29105-19 PMID: 16887808
  97. Constitutive expression of AID leads to tumorigenesis.
    J Exp Med. 2003 May 5;197(9):1173-81 PMID: 12732658
  98. Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition.
    J Mol Biol. 1998 Jan 30;275(4):695-714 PMID: 9466941
  99. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
    Hepatology. 2006 Jun;43(6):1364-74 PMID: 16729314
  100. Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting.
    Biochem J. 2003 Jan 15;369(Pt 2):255-62 PMID: 12374571
  101. E-proteins directly regulate expression of activation-induced deaminase in mature B cells.
    Nat Immunol. 2003 Jun;4(6):586-93 PMID: 12717431
  102. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine.
    Cell. 1987 Sep 11;50(6):831-40 PMID: 3621347
  103. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1.
    J Biol Chem. 2000 Jul 28;275(30):22663-9 PMID: 10833526
  104. APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis.
    J Virol. 2011 Oct;85(19):9726-36 PMID: 21775448
  105. The mechanisms regulating the subcellular localization of AID.
    Nucleus. 2010 Jul-Aug;1(4):325-31 PMID: 21327080
  106. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules.
    J Virol. 2007 Mar;81(5):2165-78 PMID: 17166910
  107. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
    J Virol. 2011 Nov;85(21):11220-34 PMID: 21835787
  108. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    PLoS Pathog. 2007 Feb;3(2):e15 PMID: 17291161
  109. Analysis of protein complexes assembled on apolipoprotein B mRNA for mooring sequence-dependent RNA editing.
    Methods. 1998 May;15(1):27-39 PMID: 9614650
  110. Negative regulation of activation-induced cytidine deaminase in B cells.
    Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2752-7 PMID: 16477013
  111. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
    Nucleic Acids Res. 2006 Jan 10;34(1):89-95 PMID: 16407327
  112. Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene.
    Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8522-6 PMID: 8078915
  113. Active nuclear import and cytoplasmic retention of activation-induced deaminase.
    Nat Struct Mol Biol. 2009 May;16(5):517-27 PMID: 19412186
  114. Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy.
    J Biol Chem. 2010 Mar 5;285(10):7111-8 PMID: 20022958
  115. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition.
    Nucleic Acids Res. 2007;35(9):2955-64 PMID: 17439959
  116. In vitro apolipoprotein B mRNA editing: identification of a 27S editing complex.
    Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1489-93 PMID: 1996349
  117. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Curr Biol. 2006 Mar 7;16(5):480-5 PMID: 16527742
  118. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals.
    Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8483-7 PMID: 7667315
  119. APOBEC-1 complementation factor (ACF) forms RNA-dependent multimers.
    Biochem Biophys Res Commun. 2010 Jul 16;398(1):38-43 PMID: 20541536
  120. Partial characterization of the auxiliary factors involved in apolipoprotein B mRNA editing through APOBEC-1 affinity chromatography.
    J Biol Chem. 1997 Oct 31;272(44):27700-6 PMID: 9346911
  121. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA.
    Mol Cell Biol. 2000 Mar;20(5):1846-54 PMID: 10669759
  122. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.
    Virology. 2008 Mar 1;372(1):136-46 PMID: 18023836
  123. Metabolic regulation of apoB mRNA editing is associated with phosphorylation of APOBEC-1 complementation factor.
    Nucleic Acids Res. 2006 Jul 04;34(11):3299-308 PMID: 16820530
  124. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15588-93 PMID: 17030807
  125. Post-translational regulation of activation-induced cytidine deaminase.
    Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):667-73 PMID: 19010772
  126. Identification of the yeast cytidine deaminase CDD1 as an orphan C-->U RNA editase.
    Nucleic Acids Res. 2001 Apr 15;29(8):1772-80 PMID: 11292850
  127. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).
    Cell. 2000 Sep 1;102(5):565-75 PMID: 11007475
  128. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.
    J Virol. 2009 Aug;83(15):7547-59 PMID: 19458006
  129. A guide to RNA editing.
    RNA. 1997 Oct;3(10):1105-23 PMID: 9326486
  130. Alternative splicing regulates activation-induced cytidine deaminase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells.
    Blood. 2008 Dec 1;112(12):4675-82 PMID: 18684869
  131. Carboxy-terminal domain of AID required for its mRNA complex formation in vivo.
    Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2747-51 PMID: 19196959
  132. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
    Genomics. 2002 Mar;79(3):285-96 PMID: 11863358
  133. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.
    Retrovirology. 2007 Jul 16;4:48 PMID: 17631688
  134. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation.
    J Exp Med. 2006 Apr 17;203(4):865-70 PMID: 16606671
  135. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  136. Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast.
    Biochemistry (Mosc). 2011 Jan;76(1):131-46 PMID: 21568845
  137. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.
    Blood. 2003 Jun 15;101(12):4903-8 PMID: 12586616
  138. Complex regulation and function of activation-induced cytidine deaminase.
    Trends Immunol. 2011 May;32(5):194-201 PMID: 21493144
  139. Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function.
    Mol Biol Evol. 2011 Mar;28(3):1125-9 PMID: 21172829
  140. Commitment of apolipoprotein B RNA to the splicing pathway regulates cytidine-to-uridine editing-site utilization.
    Biochem J. 2001 Nov 1;359(Pt 3):697-705 PMID: 11672445
  141. Proteasomal degradation restricts the nuclear lifespan of AID.
    J Exp Med. 2008 Jun 9;205(6):1357-68 PMID: 18474627
  142. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
    PLoS Pathog. 2006 May;2(5):e41 PMID: 16699599
  143. Functional characterization of APOBEC-1 complementation factor phosphorylation sites.
    Biochim Biophys Acta. 2007 Mar;1773(3):408-18 PMID: 17229474
  144. Identification of novel alternative splice variants of APOBEC-1 complementation factor with different capacities to support apolipoprotein B mRNA editing.
    J Biol Chem. 2004 Jan 2;279(1):197-206 PMID: 14570923
  145. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
    J Virol. 2007 Dec;81(23):13112-24 PMID: 17881443
Article Info
Journal
Seminars in cell & developmental biology
Abbr.
Semin Cell Dev Biol
ISSN
1096-3634
DOI
10.1016/j.semcdb.2011.10.004
Email
harold.smith@rochester.edu
Published
2012-05-00
Epub
2011-00-06
Pages
258-68
Language
English
Region
England
NLM ID
9607332
PMCID
PMC4017262
Subset
IM
Grants
NIDDK NIH HHS · R01 DK043739-08A2 · United States
NIAID NIH HHS · AI58789 · United States
NIGMS NIH HHS · R01 GM110119 · United States
NIDDK NIH HHS · R01 DK043739 · United States
NIGMS NIH HHS · GM068411 · United States
NINDS NIH HHS · R21 NS067671 · United States
NIAID NIH HHS · R21 AI058789-01 · United States
NIAID NIH HHS · R21 AI054369 · United States
PHS HHS · P30 078498 · United States
NIAID NIH HHS · AI095007 · United States
NIAID NIH HHS · R21 AI076085 · United States
NIAID NIH HHS · R21 AI095007 · United States
NIGMS NIH HHS · R01 GM110568 · United States
NIAID NIH HHS · R21 AI054369-01 · United States
NIDDK NIH HHS · DK43739 · United States
NIDDK NIH HHS · R01 DK043739-07S1 · United States
NIAID NIH HHS · R21 AI095007-01A1 · United States
NIDDK NIH HHS · R01 DK043739-09 · United States
NIAID NIH HHS · AI54369 · United States
NIAID NIH HHS · R21 AI095007-02 · United States
NIAID NIH HHS · R21 AI054369-02 · United States
NIGMS NIH HHS · T32 GM068411 · United States
NIDDK NIH HHS · R01 DK043739-11 · United States
NIAID NIH HHS · R21 AI058789 · United States
NIAID NIH HHS · R21 AI058789-02 · United States
NIAID NIH HHS · AI076085 · United States
NIDDK NIH HHS · R01 DK043739-10 · United States
NINDS NIH HHS · R21 NS067671-01S1 · United States
NINDS NIH HHS · R21 NS067671-01 · United States
NIDDK NIH HHS · R01 DK043739-07 · United States
NINDS NIH HHS · NS067671 · United States
NIAID NIH HHS · R33 AI076085 · United States
External Links
PubMed source DOI: 10.1016/j.semcdb.2011.10.004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2